Holen Sie sich die Stockscreener-App
34.65
1.35%
0.46
Handel nachbörslich:
34.79
0.14
+0.40%
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Trading Systems Reacting to (COLL) Volatility - Stock Traders Daily
COLL Stock Price, Quote & Chart - ChartMill
Collegium Pharmaceutical Inc. Q1 2026 Earnings: EPS Surges Past Estimates on Strong Operational Execution - newsline.com
COLLEGIUM PHARMACEUTICAL (COLL) director exercises options, now holds 112,483 shares - Stock Titan
Collegium Pharmaceutical grants 50,305 RSUs to 34 new hires as inducement under Nasdaq rules. - Pluang
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
2 Reasons to Sell COLL and 1 Stock to Buy Instead - Yahoo Finance
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - Yahoo Finance
Collegium Pharmaceutical Gains Attention on Strong ADHD Portfolio and Q1 2026 BeatEPS Revision Trend - thelegaladvocate.com
This Insider Has Just Sold Shares In Collegium Pharmaceutical - 富途牛牛
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio - Insider Monkey
Collegium to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Investors can stream Collegium's Jefferies healthcare fireside chat live - Stock Titan
Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS® from Corium Therapeutics - geneonline.com
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - TradingView
(COLL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story - simplywall.st
Collegium Pharmaceutical stock (US19459E1029): insider trade draws attention as Wall Street sees ups - AD HOC NEWS
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952 - Stock Titan
Collegium Pharma Leans on ADHD to Drive Growth - TipRanks
Collegium pharmaceutical director sells $142k in shares By Investing.com - Investing.com Australia
Collegium pharmaceutical director sells $142k in shares - Investing.com India
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL) - Stock Titan
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL) - Stock Titan
Collegium (COLL) director sells shares, exercises options and receives RSU grant - Stock Titan
Director at Collegium (COLL) awarded 17,482 restricted stock units - Stock Titan
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award - Stock Titan
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant - Stock Titan
COLL (NASDAQ) Form 144 shows 4,127-share sale and 30-share resale notice - Stock Titan
Collegium Pharmaceutical (COLL) director Donovan Glancy files initial Form 3 - Stock Titan
Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Have Collegium Pharmaceutical Insiders Been Selling Stock? - simplywall.st
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Collegium Pharmaceutical stock (US19459E1029): opioid-pain specialist in focus after Q1 2026 earning - AD HOC NEWS
Collegium Shareholders Back Board, Pay and Auditor Choices - TipRanks
Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting - Stock Titan
Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade - Stock Titan
Janus Henderson (COLL) reports 1.83M-share, 5.8% holding in PHARMACEUTICAL, INC. - Stock Titan
[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure - Stock Titan
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - 富途牛牛
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating - Moomoo
Renaissance files 4.53% holding in PHARMACEUTICAL, INC (COLL) - Stock Titan
Barclays Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Statutory Profit Doesn't Reflect How Good Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are - simplywall.st
Collegium Pharmaceutical's (NASDAQ:COLL) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics stocks trade down, what you need to know - MSN
Collegium (NASDAQ: COLL) director exercises options, sells 8,700 shares at $37 - Stock Titan
Earnings call transcript: Collegium Pharmaceutical Q1 2026 beats estimates By Investing.com - Investing.com Canada
Collegium Pharmaceutical Acquires AZSTARYS®, Expanding ADHD Portfolio and Raising 2026 Financial Guidance - Minichart
Collegium Pharmaceutical (NASDAQ: COLL) group filings show shared 4.7% positions - Stock Titan
Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance - Moomoo
TradingKey - TradingKey
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):